Recent Updates
Recently added Catalysts

TAK-041

Phase 2

Stable Schizophrenia | Small molecule | Psychiatry |Neurocrine Biosciences, Inc.|Last Updated: Mar 19, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment23

FDA Designations

No designations recorded

Clinical trial landscape

TAK-041 · 2 trials · 3 indications

Phase 2 1Phase 1 1
NCT03319953A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable SchizophreniaStable Schizophrenia
COMPLETED23 Analytics
PHASE2COMPLETED
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
Stable SchizophreniaUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration
Baseline (Day -1) and Day 14

BACS is a reliable and sensitive measure of cognitive function in schizophrenia. The BACS consists of items across six subtests: Verbal Memory, Digit Sequencing, Token Motor, Verbal Fluency, Symbol Coding, and Tower of London. The subtest scale scores were used to compute a composite BACS t-score of 50 (20) is the mean (standard deviation) of a relevant index population. Higher values indicate better performance. Bayesian normal linear model was used for analysis.

Blood-Oxygen-Level-Dependent (BOLD) Signal in the Average Ventral Striatum (VS) Region of Interest (ROI) Activation in the Monetary Incentive Delay (MID) Reward Task at First Testing After TAK-041 Administration
Day 1

Blood-oxygen-level-dependent imaging, or BOLD-contrast imaging, is a method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time. The MID task is a reward anticipation paradigm that robustly engages the VS, a key area associated with coding incentive reward. Dysfunctional processing of reward information is associated with motivational impairments in schizophrenia. Motivational impairment is a key aspect of negative symptoms, and has been associated with reduced activity in the VS. Any change in BOLD signal that comes in fMRI is reported.

Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
From the first dose of study drug up to 42 days after the last dose of study drug (Up to 12 weeks)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug or due to a study procedure; it did not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an AE that occurred or worsened after receiving the first dose of study drug and within 6 weeks after the last dose of study drug. A TEAE may also have been a pre-treatment AE or a concurrent medical condition diagnosed before the date of first dose of study drug that increased in severity after the start of dosing.

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)
From the first dose of study drug up to 42 days after the last dose of study drug (Up to 12 weeks)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug or due to a study procedure; it did not necessarily have to have a causal relationship with this treatment.

Percentage of Participants With Markedly Abnormal Value (MAV) Criteria for Safety Laboratory Tests At Least Once Post-dose
From the first dose of study drug up to 42 days after the last dose of study drug (Up to 12 weeks)

Clinical laboratory tests included serum chemistry, hematology and urinalysis. MAV criteria:Alanine aminotransferase(U/L) \>3 x upper limit of normal(ULN);albumin\<2.5g/dL,\<25g/L;alkaline phosphatase (U/L)\>3 x ULN; aspartate aminotransferase (U/L)\>3 x ULN;bicarbonate\<8.0 mmol/L; bilirubin\>2.0mg/dL, \>34.2 μmol/L;blood urea nitrogen\>30 mg/dL,\>10.7mmol/L;calcium\<7.0 mg/dL,\<1.75 mmol/L, \>11.5 mg/dL,\>2.88 mmol/L;chloride\<75 mmol/L,\>126 mmol/L;creatine kinase(U/L) \>5 xULN; creatinine\>2.0 mg/dL,\>177μmol/L;direct bilirubin\>2 x ULN;gamma glutamyl transferase (U/L)\>3 x ULN;glucose\<50 mg/dL,\<2.8 mmol/L,\>350 mg/dL,\>19.4 mmol/L;potassium\<3.0 mmol/L \>6.0 mmol/L; protein(g/L)\<0.8 x LLN \>1.2 x ULN;sodium\<130mmol/L \>150mmol/L;erythrocytes(10\^12erythrocytes/L) \<0.8 x LLN,\>1.2 x ULN;hematocrit(fraction of 1)\<0.8 x LLN,\>1.2xULN;hemoglobin(g/L)\<0.8 x LLN\>1.2 x ULN;leukocytes(10\^9 leukocytes/L)\<0.5 x LLN \>1.5 x ULN;platelets(10\^9 platelets/L)\<75-\>600. Categories with at least one participant are reported.

Percentage of Participants With Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose
From the first dose of study drug up to 42 days after the last dose of study drug (Up to 12 weeks)

Vital signs included oral body temperature measurement, supine and standing blood pressure, respiration rate, and pulse. Pulse and blood pressure was measured after 5 minutes supine and again at 1 and 3 minutes after standing. The markedly abnormal value (MAV) criteria for vital signs included systolic blood pressure \< 85 mmHg, \> 180 mmHg; diastolic blood pressure \< 50 mmHg, \> 110 mmHg; pulse \< 50 beats/min, \> 120 beats/min; temperature \< 35.6 C \> 37.7 C. Categories with data in at least one arm group are reported.

Percentage of Participants With Markedly Abnormal Criteria for 12-Lead Electrocardiogram (ECG) Parameters at Least Once Post-dose
From the first dose of study drug up to 42 days after the last dose of study drug (Up to 12 weeks)

The markedly abnormal value (MAV) criteria for 12-lead ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec). Categories with data in at least one arm group are reported.

Part 2: Percentage of Participants Who Experienced Clinically Significant Abnormal Changes in Continuous 12-Lead Holter ECG Measurements at Least Once Post-Dose
Part 2: from first dose up to Day 66

The markedly abnormal value (MAV) criteria for continuous 12-lead Holter ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec). Categories with data in at least one arm group are reported.

Part 3: Cmax: Maximum Observed Plasma Concentration for TAK-041 in RBA/Food Effect Participants [Day 1]
Part 3: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
Part 3: AUC96: Area Under the Plasma Concentration-Time Curve From Time 0 to 96 Hours (AUC96) for TAK-041 in RBA/Food Effect Participants [Day 1]
Part 3: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose

Secondary Endpoints

Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements At Least Once Post Dose
From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Treatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsEXPERIMENTALTAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Treatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsEXPERIMENTALTAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Treatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsEXPERIMENTALTAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Treatment Sequence 4: Placebo/TAK-041 160 mg + AntipsychoticsEXPERIMENTALTAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
Part 1 (SRD): Placebo Cohorts 1-5PLACEBO_COMPARATORTAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
Part 1 (SRD): Cohort 1: TAK-041 5/20 mgEXPERIMENTALTAK-041 5 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 20 mg, suspension, orally, once on Day 8 in the SRD period.
Part 1 (SRD): Cohort 2: TAK-041 10/40 mgEXPERIMENTALTAK-041 10 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 40 mg, suspension, orally, once on Day 8 in the SRD period.
Part 1 (SRD): Cohort 3: TAK-041 80 mgEXPERIMENTALTAK-041 80 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
Part 1 (SRD): Cohort 4: TAK-041 120 mgEXPERIMENTALTAK-041 120 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
Part 1 (SRD): Cohort 5: TAK-041 160 mgEXPERIMENTALTAK-041 160 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
Part 2 (MRD): Placebo Cohorts 1-4PLACEBO_COMPARATORTAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the multiple-rising dose (MRD) period.
Part 2 (MRD): Cohort 1: TAK-041 40/20 mgEXPERIMENTALTAK-041 40 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 20 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
Part 2 (MRD): Cohort 2: TAK-041 80/40 mgEXPERIMENTALTAK-041 80 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 40 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
Part 2 (MRD): Cohort 3: TAK-041 120/60 mgEXPERIMENTALTAK-041 120 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 60 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
Part 2 (MRD): Cohort 4: TAK-041 160/80 mgEXPERIMENTALTAK-041 160 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
Part 3: Relative Bioavailability (RBA)/Food Effect: Regimen AEXPERIMENTALTAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1.
Part 3: RBA/Food Effect: Regimen BEXPERIMENTALTAK-041 40 mg, tablet, orally, once on Day 1 in fed state (Regimen B) in Cohort 2.
Part 4: MRD: PlaceboPLACEBO_COMPARATORTAK-041 placebo-matching, suspension, orally, on Days 1, 8, 15 and 22 in participants with schizophrenia
Part 4: MRD: TAK-041 160/80 mgEXPERIMENTALTAK-041 160 mg as loading dose, suspension, orally, once on Day 1 followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in participants with schizophrenia.

Interventions

NameTypeDescription
TAK-041DRUGTAK-041 suspension
PlaceboDRUGTAK-041 placebo-matching suspension
Second Generation Antipsychotics (SGA)DRUGSecond generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
TAK-041 PlaceboDRUGTAK-041 placebo-matching suspension or tablet.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Is on a stable dose of antipsychotics for at least 2 months as documented by medical history and assessed by site staff (other than those on the excluded medication list). 2. Meets schizophrenia criteria as defined by the Diagnostic and Statistical Manual of Mental Disorders ...

Countries:United KingdomUnited States
Unlock Eligibility Criteria

Frequently asked questions about TAK-041

What is TAK-041 used for?

TAK-041 is an investigational small molecule being studied for use in stable schizophrenia and in healthy volunteers. It is being developed by Neurocrine Biosciences, Inc. (NBIX) as a potential treatment for psychiatric conditions, with clinical trials conducted in the United States and the United Kingdom.

Who makes TAK-041?

TAK-041 is being developed by Neurocrine Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol NBIX. The drug is an investigational small molecule in the psychiatry therapeutic area, currently in clinical development for stable schizophrenia.

What phase is TAK-041 in?

TAK-041 is in Phase 1 clinical development. A Phase 1 first-in-human study has been completed, and a Phase 2 proof of activity study in stable schizophrenia has also been completed. The drug remains investigational and is not yet approved by regulatory authorities.

What clinical trials is TAK-041 in?

TAK-041 has been studied in two completed clinical trials. NCT02748694 was a Phase 1 first-in-human safety, tolerability, and pharmacokinetics study in healthy volunteers and schizophrenia patients. NCT03319953 was a Phase 2 randomized, double-blind, placebo-controlled proof of activity study in stable schizophrenia.

Is TAK-041 the same as any other drug?

No alternative names for TAK-041 have been disclosed. The drug is identified solely by its code name TAK-041 in clinical trial registries and by its developer, Neurocrine Biosciences, Inc.